Loxo Oncology, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014
Operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of premium and discounts on investments
Depreciation of property and equipment
Stock-based compensation
Issuance of redeemable convertible preferred stock in connection with collaboration agreement
Changes in operating assets and liabilities:
Decrease (increase) in prepaid expenses and other assets
Security deposits
Increase in accounts payable
Increase in accrued expenses and other current liabilities
Increase in deferred revenue

Net cash provided by (used in) operating activities
Investing activities:
Purchases of available-for-sale securities
Proceeds from maturing available-for-sale securities
Purchase of property and equipment
Net cash used in investing activities
Financing activities:
Proceeds from issuance of redeemable convertible preferred stock, net
Proceeds from issuance of common stock, net
Proceeds from the exercise of stock options
Payment of deferred financing fees
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents-beginning of year
Cash and cash equivalents-end of year

Unrealized gain (loss) on available-for-sale securities
Supplemental schedule of noncash financing activities:
Conversion of redeemable convertible preferred stock into common stock
Reclassification of share repurchase obligation

Comments